Article

Anxiety comorbidity and quality of life in bipolar disorder patients.

Department of Biochemistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Canadian journal of psychiatry. Revue canadienne de psychiatrie (Impact Factor: 2.41). 04/2007; 52(3):175-81.
Source: PubMed

ABSTRACT To assess the impact of anxiety comorbidity on the quality of life of patients with bipolar disorder (BD).
We undertook a cross-Sectional survey of 162 BD outpatients interviewed with the Structured Clinical Interview for DSM-IV. The primary outcome measure was quality of life, assessed with the 26-item WHO Quality of Life Instrument (WHOQOL-BREF).
Anxiety comorbidity in BD patients was associated with lower scores in all domains of quality of life. The impact of anxiety comorbidity on the psychological domain of the WHOQOL-BREF was kept, even when the current level of depression was added to the model as a confounding factor. Current anxiety comorbidity was also associated with lifetime alcohol abuse and dependence, rapid cycling, lifetime psychosis, number of suicide attempts, and a lower score in the Global Assessment of Functioning measure.
Our findings suggest that anxiety comorbidity in BD patients is related to lower quality of life, particularly on the psychological domain. BD-anxiety comorbidity may be associated with such markers of illness severity as number of suicide attempts, rapid cycling, lifetime alcohol abuse, and psychosis. The recognition and treatment of anxiety comorbidity may help patients with BD to relieve their psychological pain and improve their overall quality of life.

Download full-text

Full-text

Available from: Keila Ceresér, May 11, 2014
1 Follower
 · 
156 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This study discusses a personalized wearable monitoring system which provides information and communication technologies to patients with mental disorders and physicians managing such diseases. The system, hereinafter called the PSYCHE system, is mainly comprised of a comfortable t-shirt with embedded sensors, such as textile electrodes, to monitor electrocardiogram-Heart Rate Variability (HRV) series, piezoresistive sensors for respiration activity, and tri-axial accelerometers for activity recognition. Moreover, on the patient-side, PSYCHE system uses a smartphone-based interactive platform for electronic mood agenda and clinical scale administration, whereas on the physician-side provides data visualization and support to clinical decision. The smartphone collects the physiological and behavioral data and sends the information out to a centralized server for further processing. In this study, we present experimental results gathered from ten bipolar patients, wearing the PSYCHE system, with severe symptoms who exhibited mood states among depression (DP), hypomania(HM), mixed state (MX), and euthymia (EU), i.e., the good affective balance. In analyzing more than 400 hours of cardiovascular dynamics, we found that patients experiencing mood transitions from a pathological mood state (HM, DP or MX - where depressive and hypomanic symptoms are simultaneously present) to EU can be characterized through a commonly used measure of entropy. In particular, the SampEn estimated on long term HRV series increases according to the patients' clinical improvement. These results are in agreement with the current literature reporting on the complexity dynamics of physiological systems and provides a promising and viable support to clinical decisionin order to improve the diagnosis and management of psychiatric disorders.
    IEEE Journal of Biomedical and Health Informatics 09/2014; 19(1). DOI:10.1109/JBHI.2014.2360711 · 1.98 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Previous research on functional outcome in bipolar disorder (BD) has uncovered various factors that exacerbate psychosocial disability over the course of illness, including genetics, illness severity, stress, anxiety, and cognitive impairment. This paper presents an integrated view of these findings that accounts for the precipitous decline in psychosocial functioning after illness onset. The proposed model highlights a number of reciprocal pathways among previously studied factors that trap people in a powerful cycle of ailing forces. The paper discusses implications to patient care as well as the larger social changes required for shifting the functional trajectory of people with BD from psychosocial decline to growth.
    Depression research and treatment 01/2012; 2012(2090-1321):949248. DOI:10.1155/2012/949248
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objective. Many patients with bipolar disorder take adjunctive medications for anxiety. Using naturalistic data, we investigated the relationship between the use of adjunctive anxiolytics and the time spent in episodes or with subsyndromal mood symptoms. Methods. This was a post-hoc analysis of 310 patients with bipolar disorder who previously recorded mood and medications daily for 5 months using ChronoRecord software. One hundred patients were taking adjunctive anxiolytics for at least 50% of days; 210 were not. Of the 100 patients, 73 were taking a benzodiazepine. All patients taking anxiolytics were also receiving treatments for bipolar disorder. Results. Patients with bipolar disorder who were taking adjunctive medications for anxiety spent more time ill. Comparing patients who were taking or not taking anxiolytics, the mean days spent either in any episode or with subsyndromal symptoms was 45.6 vs. 29.6%, respectively (P B0.001), the mean days in any episode was 17.1 vs. 9.2%, respectively (P 00.016), and the mean days with subsyndromal depression was 26.4 vs. 16.2%, respectively (P 00.004). Conclusion. While this methodology cannot determine causality, these findings highlight the need for controlled studies of the long-term impact of adjunctive medications for anxiety on mood symptoms in patients being treated for bipolar disorder.
    International Journal of Psychiatry in Clinical Practice 07/2009; 13(1). DOI:10.1080/13651500802450514 · 1.31 Impact Factor